Literature DB >> 18582534

Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFalpha, and INFgamma concentrations are elevated in patients with atypical and idiopathic parkinsonism.

Bogdan Brodacki1, Jacek Staszewski, Beata Toczyłowska, Ewa Kozłowska, Nadzieja Drela, Małgorzata Chalimoniuk, Adam Stepien.   

Abstract

We investigated serum levels of interleukin (IL)-2, IL-10, IL-6, IL-4, TNFalpha, INFgamma in 7 patients with atypical parkinsonism (AP), 31 idiopathic PD (iPD) patients, 17 idiopathic PD with cardiovascular risk factor (iPD-CVRF) patients, and 20 age-matched controls (healthy, non-parkinsonian patients). Cytokine concentrations were measured using the Becton Dickinson (BD) human Th1/Th2 Cytokine kit II with a flow cytometry system. The concentrations of IL-2, IL-10, IL-4, IL-6, TNFalpha, and INFgamma were detectable in the serum from all groups, including the control. Increased serum IL-2, IL-10, IL-4, IL-6, TNFalpha, and INFgamma concentrations were found in all groups of parkinsonian patients, as compared to the control group. The highest elevations of serum IL-2, IL-4, IL-6, TNFalpha, and INFgamma concentrations were observed in AP patients, as compared to the iPD and iPD-CVRF groups. However, the serum IL-6 concentration was higher in the iPD-CVRF group than in the iPD group. The IL-10 level was significantly higher in all groups of PD patients relative to the control group, but was the lowest in the serum from the AP patients. Moreover, the serum levels of lipid peroxidation products were enhanced 2.1- and 1.5-fold in AP and both iPD groups, respectively. These results argue in favor of the involvement of immunological events in the process of neurodegeneration in AP and PD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18582534     DOI: 10.1016/j.neulet.2008.06.040

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  91 in total

1.  Therapeutic attenuation of neuroinflammation and apoptosis by black tea theaflavin in chronic MPTP/probenecid model of Parkinson's disease.

Authors:  Annadurai Anandhan; Musthafa Mohamed Essa; Thamilarasan Manivasagam
Journal:  Neurotox Res       Date:  2012-06-06       Impact factor: 3.911

2.  Chronic dichlorvos exposure: microglial activation, proinflammatory cytokines and damage to nigrostriatal dopaminergic system.

Authors:  B K Binukumar; Amanjit Bal; Kiran Dip Gill
Journal:  Neuromolecular Med       Date:  2011-10-04       Impact factor: 3.843

3.  IL6 protects MN9D cells and midbrain dopaminergic neurons from MPP+-induced neurodegeneration.

Authors:  Björn Spittau; Xiaolai Zhou; Ming Ming; Kerstin Krieglstein
Journal:  Neuromolecular Med       Date:  2012-07-08       Impact factor: 3.843

4.  Microglia, inflammation and gut microbiota responses in a progressive monkey model of Parkinson's disease: A case series.

Authors:  Valerie Joers; Gunasingh Masilamoni; Doty Kempf; Alison R Weiss; Travis M Rotterman; Benjamin Murray; Gul Yalcin-Cakmakli; Ronald J Voll; Mark M Goodman; Leonard Howell; Jocelyne Bachevalier; Stefan J Green; Ankur Naqib; Maliha Shaikh; Phillip A Engen; Ali Keshavarzian; Christopher J Barnum; Jonathon A Nye; Yoland Smith; Malú G Tansey
Journal:  Neurobiol Dis       Date:  2020-07-24       Impact factor: 5.996

5.  Interferon-γ Involvement in the Neuroinflammation Associated with Parkinson's Disease and L-DOPA-Induced Dyskinesia.

Authors:  D P Ferrari; M Bortolanza; E A Del Bel
Journal:  Neurotox Res       Date:  2021-03-09       Impact factor: 3.911

6.  Dexmedetomidine Regulates 6-hydroxydopamine-Induced Microglial Polarization.

Authors:  Pei Zhang; Yu Li; Xuechang Han; Qunzhi Xing; Lei Zhao
Journal:  Neurochem Res       Date:  2017-02-28       Impact factor: 3.996

Review 7.  Innate and adaptive immune responses in Parkinson's disease.

Authors:  Aubrey M Schonhoff; Gregory P Williams; Zachary D Wallen; David G Standaert; Ashley S Harms
Journal:  Prog Brain Res       Date:  2019-12-05       Impact factor: 2.453

Review 8.  Parkinson's disease.

Authors:  Timothy R Mhyre; James T Boyd; Robert W Hamill; Kathleen A Maguire-Zeiss
Journal:  Subcell Biochem       Date:  2012

9.  Attention-deficit hyperactivity disorder (ADHD) and glial integrity: an exploration of associations of cytokines and kynurenine metabolites with symptoms and attention.

Authors:  Robert D Oades; Aye-Mu Myint; Maria R Dauvermann; Benno G Schimmelmann; Markus J Schwarz
Journal:  Behav Brain Funct       Date:  2010-06-09       Impact factor: 3.759

10.  Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease.

Authors:  Vanesa Sanchez-Guajardo; Fabia Febbraro; Deniz Kirik; Marina Romero-Ramos
Journal:  PLoS One       Date:  2010-01-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.